|
1
|
Aozasa K, Ohsawa M, Tajima K, Sasaki R,
Maeda H, Matsunaga T and Friedmann I: Nation-wide study of lethal
mid-line granuloma in Japan: frequencies of wegener’s granulo
matosis, polymorphic reticulosis, malignant lymphoma and other
related conditions. Int J Cancer. 44:63–66. 1989.PubMed/NCBI
|
|
2
|
Kim GE, Cho JH, Yang WI, Chung EJ, Suh CO,
Park KR, Hong WP, Park IY, Hahn JS, Roh JK and Kim BS: Angiocentric
lymphoma of the head and neck: patterns of systemic failure after
radiation treatment. J Clin Oncol. 18:54–63. 2000.PubMed/NCBI
|
|
3
|
Lee J, Park YH, Kim WS, Lee SS, Ryoo BY,
Yang SH, Park KW, Kang JH, Park JO, Lee SH, Kim K, Jung CW, Park
YS, Im YH, Kang WK, Lee MH, Ko YH, Ahn YC and Park K: Extranodal
nasal type NK/T-cell lymphoma: elucidating clinical prognostic
factors for risk-based stratification of therapy. Eur J Cancer.
41:1402–1408. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Egger G, Liang G, Aparicio A and Jones PA:
Epigenetics in human disease and prospects for epigenetic therapy.
Nature. 429:457–463. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim TM, Park YH, Lee SY, Kim JH, Kim DW,
Im SA, Kim TY, Kim CW, Heo DS, Bang YJ, Chang KH and Kim NK: Local
tumor invasiveness is more predictive of survival than
International Prognostic Index in stage I(E)/II(E) extranodal
NK/T-cell lymphoma, nasal type. Blood. 106:3785–3790. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee
JH, Lee DH, Huh J, Oh SY, Kwon HC, Kim HJ, Lee SI, Kim JH, Park J,
Oh SJ, Kim K, Jung C, Park K and Kim WS: Extranodal natural killer
T-cell lymphoma, nasal-type: a prognostic model from a
retrospective multicenter study. J Clin Oncol. 24:612–618. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yamaguchi M: Current and future management
of NK/T-cell lymphoma based on clinical trials. Int J Hematol.
96:562–571. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ueno T, Ohtawa K, Mitsui K, Kodera Y,
Hiroto M, Matsushima A, Inada Y and Nishimura H: Cell cycle arrest
and apoptosis of leukemia cells induced by L-asparaginase.
Leukemia. 11:1858–1861. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Richards NG and Schuster SM: Mechanistic
issues in asparagine synthetase catalysis. Adv Enzymol Relat Areas
Mol Biol. 72:145–198. 1998.PubMed/NCBI
|
|
10
|
Chen H, Pan YX, Dudenhausen EE and Kilberg
MS: Amino acid deprivation induces the transcription rate of the
human asparagine synthetase gene through a timed program of
expression and promoter binding of nutrient-responsive bZIP
transcription factors as well as localized histone acetylation. J
Biol Chem. 279:50829–50839. 2004. View Article : Google Scholar
|
|
11
|
Kilberg MS, Pan YX, Chen H and
Leung-Pineda V: Nutritional control of gene expression: how
mammalian cells respond to amino acid limitation. Annu Rev Nutr.
25:59–85. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li BS, Gu LJ, Luo CY, Li WS, Jiang LM,
Shen SH, Jiang H, Shen SH, Zhang B, Chen J, Xue HL and Tang JY: The
downregulation of asparagine synthetase expression can increase the
sensitivity of cells resistant to L-asparaginase. Leukemia.
20:2199–2201. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hashimoto K, Suzuki F and Sakagami H:
Declined asparagine synthetase mRNA expression and enhanced
sensitivity to asparaginase in HL-60 cells committed to monocytic
differentiation. Anticancer Res. 29:1303–1308. 2009.PubMed/NCBI
|
|
14
|
Aslanian AM, Fletcher BS and Kilberg MS:
Asparagine synthetase expression alone is sufficient to induce
L-asparaginase resistance in MOLT-4 human leukaemia cells. Biochem
J. 357:321–328. 2001. View Article : Google Scholar
|
|
15
|
Zwaan CM, Kaspers GJ, Pieters R, Hahlen K,
Janka-Schaub GE, van Zantwijk CH, Huismans DR, de Vries E, Rots MG,
Peters GJ, Jansen G, Creutzig U and Veerman AJ: Different drug
sensitivity profiles of acute myeloid and lymphoblastic leukemia
and normal peripheral blood mononuclear cells in children with and
without Down syndrome. Blood. 99:245–251. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lorenzi PL, Llamas J, Gunsior M, Ozbun L,
Reinhold WC, Varma S, Ji H, Kim H, Hutchinson AA, Kohn EC,
Goldsmith PK, Birrer MJ and Weinstein JN: Asparagine synthetase is
a predictive biomarker of L-asparaginase activity in ovarian cancer
cell lines. Mol Cancer Ther. 7:3123–3128. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lorenzi PL, Reinhold WC, Rudelius M,
Gunsior M, Shankavaram U, Bussey KJ, Scherf U, Eichler GS, Martin
SE, Chin K, Gray JW, Kohn EC, Horak ID, Von Hoff DD, Raffeld M,
Goldsmith PK, Caplen NJ and Weinstein JN: Asparagine synthetase as
a causal, predictive biomarker for L-asparaginase activity in
ovarian cancer cells. Mol Cancer Ther. 5:2613–2623. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cui H, Darmanin S, Natsuisaka M, Kondo T,
Asaka M, Shindoh M, Higashino F, Hamuro J, Okada F, Kobayashi M,
Nakagawa K and Koide H: Enhanced expression of asparagine
synthetase under glucose-deprived conditions protects pancreatic
cancer cells from apoptosis induced by glucose deprivation and
cisplatin. Cancer Res. 67:3345–3355. 2007. View Article : Google Scholar
|
|
19
|
Sircar K, Huang H, Hu L, Cogdell D,
Dhillon J, Tzelepi V, Efstathiou E, Koumakpayi IH, Saad F, Luo D,
Bismar TA, Aparicio A, Troncoso P, Navone N and Zhang W:
Integrative molecular profiling reveals asparagine synthetase is a
target in castration-resistant prostate cancer. Am J Pathol.
180:895–903. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang B, Dong LW, Tan YX, Zhang J, Pan YF,
Yang C, Li MH, Ding ZW, Liu LJ, Jiang TY, Yang JH and Wang HY:
Asparagine synthetase is an independent predictor of surgical
survival and a potential therapeutic target in hepatocellular
carcinoma. Br J Cancer. 109:14–23. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Swerdlow SH, Campo E, Harris NL, Jaffe ES,
Pileri SA, Stein H, Thiele J and Vardiman JWL: WHO Classification
of Tumours of Haematopoietic and Lymphoid Tissue (IARC WHO
Classification of Tumours). IARC Press; Lyon: 2008
|
|
22
|
Cheson BD, Pfistner B, Juweid ME, Gascoyne
RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca
E, et al; International Harmonization Project on Lymphoma. Revised
response criteria for malignant lymphoma. J Clin Oncol. 25:579–586.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hutson RG, Kitoh T, Moraga Amador DA,
Cosic S, Schuster SM and Kilberg MS: Amino acid control of
asparagine synthetase: relation to asparagi-nase resistance in
human leukemia cells. Am J Physiol. 272:1691–1699. 1997.PubMed/NCBI
|
|
24
|
Balasubramanian MN, Butterworth EA and
Kilberg MS: Asparagine synthetase: regulation by cell stress and
involvement in tumor biology. Am J Physiol Endocrinol Metab.
304:789–799. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fine BM, Kaspers GJ, Ho M, Loonen AH and
Boxer LM: A genome-wide view of the in vitro response to
L-asparaginase in acute lymphoblastic leukemia. Cancer Res.
65:291–299. 2005.PubMed/NCBI
|
|
26
|
Stams WA, den Boer ML, Beverloo HB,
Meijerink JP, Stigter RL, van Wering ER, Janka-Schaub GE, Slater R
and Pieters R: Sensitivity to L-asparaginase is not associated with
expression levels of asparagine synthetase in t(12; 21)+
pediatric ALL. Blood. 101:2743–2747. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Stams WA, den Boer ML, Holleman A, Appel
IM, Beverloo HB, van Wering ER, Janka-Schaub GE, Evans WE and
Pieters R: Asparagine synthetase expression is linked with
L-asparaginase resistance in TEL-AML1-negative but not
TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood.
105:4223–4225. 2005. View Article : Google Scholar
|
|
28
|
Den Boer ML, Evans WE and Pieters R:
TEL-AML1-positive ALL: a discordant genotype. Cell Cycle.
4:997–998. 2005.PubMed/NCBI
|
|
29
|
Dufour E, Gay F, Aguera K, Scoazec JY,
Horand F, Lorenzi PL and Godfrin Y: Pancreatic tumor sensitivity to
plasma L-asparagine starvation. Pancreas. 41:940–948. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tardito S, Chiu M, Uggeri J, Zerbini A, Da
Ros F, Dall’Asta V, Missale G and Bussolati O: L-Asparaginase and
inhibitors of glutamine synthetase disclose glutamine addiction of
beta-catenin-mutated human hepatocellular carcinoma cells. Curr
Cancer Drug Targets. 11:929–943. 2011. View Article : Google Scholar
|
|
31
|
Greco A, Gong SS, Ittmann M and Basilico
C: Organization and expression of the cell cycle gene, ts11, that
encodes asparagine synthetase. Mol Cell Biol. 9:2350–2359.
1989.PubMed/NCBI
|
|
32
|
Gong SS and Basilico C: A mammalian
temperature-sensitive mutation affecting G1 progression results
from a single amino acid substitution in asparagine synthetase.
Nucleic Acids Res. 18:3509–3513. 1990. View Article : Google Scholar
|
|
33
|
Patrikainen L, Porvari K, Kurkela R,
Hirvikoski P, Soini Y and Vihko P: Expression profiling of PC-3
cell line variants and comparison of MIC-1 transcript levels in
benign and malignant prostate. Eur J Clin Invest. 37:126–133. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ameri K, Luong R, Zhang H, Powell AA,
Montgomery KD, Espinosa I, Bouley DM, Harris AL and Jeffrey SS:
Circulating tumour cells demonstrate an altered response to hypoxia
and an aggressive phenotype. Br J Cancer. 102:561–569. 2010.
View Article : Google Scholar : PubMed/NCBI
|
